Theodoros Foukakis
Stockholm, AB, Sweden
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 139 publications
Variation in chemotherapy use across healthcare regions in Sweden and its impact on prognosis in women with HR+/HER2- early breast cancer.
Journal: Breast cancer research : BCR
Published: April 30, 2026
Risk stratification and relapse pattern in triple-negative breast cancer with pathological complete response after neoadjuvant treatment: the European GAMBIT real-world study.
Journal: Nature communications
Published: April 15, 2026
Assessing the methodological quality of machine learning approaches in diagnostic accuracy meta-analyses: Insights from a recent study of 109 articles.
Journal: European journal of cancer (Oxford, England : 1990)
Published: April 04, 2026
Assessment of Trophoblast cell surface antigen 2 (Trop-2) expression and its clinical significance in breast cancer: a multi-level analysis of protein and gene expression.
Journal: BMC medicine
Published: March 23, 2026
Tucatinib in patients with HER2-positive advanced/metastatic breast cancer: A systematic literature review of real-world evidence.
Journal: Breast (Edinburgh, Scotland)
Published: March 12, 2026
ASO Visual Abstract: Surgical Outcomes After Neoadjuvant Pembrolizumab Plus Chemotherapy for Triple-Negative Breast Cancer-Results from the Randomized, Placebo-Controlled Phase 3 KEYNOTE-522 Study.
Journal: Annals of surgical oncology
Published: March 12, 2026
Integrating liquid biopsies and artificial intelligence for early cancer detection: A systematic review and meta-analysis.
Journal: European journal of cancer (Oxford, England : 1990)
Published: February 19, 2026
Correction: Impact of adding palbociclib on treatment adherence to ongoing adjuvant endocrine treatment in the global randomized PALLAS randomized trial in patients with early breast cancer.
Journal: Breast cancer research and treatment
Published: February 18, 2026
A nationwide population-based study on the incidence and prognosis of HER2-positive breast cancer eligible for adjuvant pertuzumab in the modern era of neoadjuvant therapy.
Journal: Breast (Edinburgh, Scotland)
Published: February 14, 2026
Concordance between clinician-reported toxicities and patient-reported symptom severity in early-stage breast cancer: an analysis of the randomized phase III PANTHER trial.
Journal: ESMO open
Published: February 09, 2026
Variation in Pathological Appearance Across Repeated Sampling from Probably Benign Breast Lesions.
Journal: Biomedicines
Published: October 23, 2025
Surgical Outcomes After Neoadjuvant Pembrolizumab Plus Chemotherapy for Triple-Negative Breast Cancer: Results from the Randomized, Placebo-Controlled Phase 3 KEYNOTE-522 Study.
Journal: Annals of surgical oncology
Published: October 03, 2025
Last Updated: 09/26/2026